INTRODUCTION AND AIMS: Hyperkalemia (HK), commonly defined as potassium level >5.0 mmol/L, is associated with a high risk of cardiovascular events and shortterm mortality among acutely hospitalized patients and among patients with chronic kidney disease (CKD). Although HK has also been associated with prolonged stay during acute hospitalizations and with intensive care unit (ICU) and emergency department visits, overall healthcare resource utilization (HRU) and costs associated with HK among CKD patients have not been comprehensively studied. The aim of this study was to estimate the healthcare costs associated with HK in a real-world clinical setting among patients with CKD. METHODS: Patients with an incident diagnosis of CKD were identified from medical registries covering the entire population (1.8 million) of Northern Denmark between 1 January 2005 and 30 June 2011. CKD was defined as the first occurrence of: (i) second measurement (>90 days following prior measurement) of estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m 2 ; (ii) incident hospitalization with diagnosis of CKD or (iii) hospital-based procedure code for dialysis. First and subsequent HK events in primary or hospital care, i.e. blood potassium level >5.0 mmol/L, were recorded. For each CKD patient experiencing a first HK event, a CKD patient without HK was matched for comparison on the HK index date on prespecified clinical characteristics. The mean costs based on the recorded utilization of hospital-based inpatient and outpatient care, general practitioner (GP) GP services, and medications dispensed at pharmacies were measured in 2015 Euros (e) in a period of 6 months before and 6 months after the HK index date. The difference in mean costs within the defined time period was calculated in HK patients and matched non-HK comparisons, weighted by time-at-risk 6 months after HK, to account for early mortality. RESULTS: Overall 17,747 CKD patients with a first HK event were identified. Of these, 44% had a second HK event, while the proportions of patients who experienced a third (56%) or fourth (61%) event were even greater, with successively shorter time intervals between the HK events. Among this CKD cohort, accounting for mortality, overall mean costs were e9,045 higher 6 months after the first HK event compared to 6 months before the HK, while mean costs increased by only e654 in matched non-HK CKD comparisons during the same period, resulting in HK-associated costs of e8,391. Acute hospitalizations constituted 74% of the overall HK-associated costs, planned hospital admissions 21%, hospital outpatient care visits 4%, GP services 1%, and out-of-hospital medication costs remained unchanged. Costs increased with increasing severity of the HK episode. Substantial HK-associated costs were observed in CKD patients both with and without use of renin-angiotensin-aldosterone system inhibitors. CONCLUSIONS: The costs associated with HK were substantial among CKD patients, and were mainly driven by increased use of hospital-based care. The increased HRU and corresponding costs associated with HK events, as well as the recurring pattern of events among CKD patients, may incur a substantial economic burden for healthcare providers and payers. The number of patients with diabetes will grow to almost 600 million in 2035, and the vast majority has type 2 diabetes. End-stage renal disease (ESRD) is one of the most devastating complications of diabetes. Among patients entering chronic renal replacement therapy, type 2 diabetes is the most common cause of ESRD in most industrialized countries. However, very few studies have followed type 2 diabetes patients from time of diagnosis until the development of ESRD, and the long-term cumulative risk of ESRD is not well known. We aimed at estimating risk of ESRD in a complete nationwide cohort of patients with newly diagnosed type 2 diabetes and long followup. METHODS: Patients diagnosed with type 2 diabetes in 1990 to 2011 were identified from several national healthcare registries in Finland and gathered in the FinDM database. Virtually all inhabitants aged 40 years or older who started diabetes medication or were hospitalized for diabetes were included. ESRD was defined as renal replacement therapy as identified from the national renal registry. Cumulative risk of ESRD was estimated using methods that take death into account as a competing risk event. Hazard ratios of ESRD were calculated using proportional subdistribution hazards regression. RESULTS: During 1990-2011, 421 429 patients were diagnosed with type 2 diabetes and of these 1516 developed ESRD and 150 524 died before the end of 2013.
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INTRODUCTION AND AIMS:
To use published research to assess the costs and resource use associated with chronic kidney disease (CKD), including end-stage renal disease (ESRD), by comparing costs against individuals without CKD and by CKD stage. METHODS: Electronic databases (Embase, MEDLINE and the Cochrane Library) were searched in May 2017 using terms for CKD, ESRD, costs and resource utilization. Only studies published in 2012-2017 reporting costs for a population of 100 patients or more were included in the final review. RESULTS: Of the 47 relevant papers identified, nine reported data that were relevant for the purposes of this review: three studies reported costs/resource use for CKD relative to individuals without CKD, five studies reported costs by CKD stage, and one study reported data for both types of comparison. Two studies showed that the proportion of patients who experienced hospitalization was 53%-209% higher in patients with pre-dialysis CKD and 230%-698% higher in those with ESRD than in patients with normal kidney function. In addition, hospital stays were significantly longer for patients with CKD or ESRD. In a population experiencing hospitalization and surgical intervention for hip fracture, the total costs arising from this were 11% and 34% higher for patients with CKD and ESRD respectively, compared with costs for patients without CKD. Total healthcare costs in a patient population with hepatitis C were reported to be significantly higher (185%) for patients with CKD or ESRD compared with those who did not have CKD. Another study showed that direct healthcare costs were 49% higher for patients with CKD stage 1-2 than for patients without CKD and increased with disease severity to 91% higher for patients with CKD stage 3 and 695% higher for patients with CKD stage 4-5 (both compared with no CKD). Three studies showed that CKD stage 3 was associated with 9%-50% higher medical costs than CKD stages 1-2, and one study reported that patients with CKD stage 3 incurred 77% higher costs than those with CKD stage 0-2 whose disease did not progress to stage 3. Costs increased with each successive CKD stage thereafter. Five studies reported cost increases (33%-317%) for stages 4-5 (either pre-dialysis CKD or CKD with requirement for renal replacement therapy) compared with stage 3. Compared with stage 4, healthcare costs increased by 31%-71% for CKD stage 5 (with or without requirement for dialysis) in two studies. In an additional study, progression of CKD stage 4 to ESRD was associated with 77% higher costs than CKD stage 4 without progression. CONCLUSIONS: The evidence identified in this comprehensive systematic literature review has shown that CKD is associated with a significant economic burden, which increases progressively from CKD stages 1-2 to ESRD. Delay or prevention of progression might result in considerable cost savings. 
